Company news
Chiome Bioscience Inc. (TSE:4583) news
Chiome Bioscience Inc. news releases on 6ix. Latest, Aug 13, 2026: Non-Consolidated Financial Results (Japanese GAAP) for the Six Months Ended June 30,2026
Press releases & updates
Non-Consolidated Financial Results (Japanese GAAP) for the Six Months Ended June 30,2026
August 13, 2026
Chiome Bioscience : Announcement of target-specific research and option agreement with Heidelberg Pharma
July 13, 2022
Chiome Bioscience : Service agreement with option contract with Rohto Pharmaceutical Co., Ltd.
July 11, 2022
Chiome Bioscience : First patient in of cancer therapeutic antibody CBA-1535 in a Phase 1 clinical trial
July 4, 2022
Chiome Bioscience : Conclusion of contract with additional institutes and first dosing of CBA-1205 in the second part of Phase 1 study
June 13, 2022
Chiome Bioscience : Submission of the application for a Phase I study of CBA-1535
February 16, 2022
Chiome Bioscience : License agreement for a diagnostic kit with Fujirebio, Inc.
February 15, 2022
Chiome Bioscience : Supplementary Information for Financial Results FY12/21
February 14, 2022
Chiome Bioscience : Non-Consolidated Financial Results (Japanese GAAP) for the Fiscal Year Ended December 31, 2021
February 14, 2022
Chiome Bioscience : Move to the second half part of Phase 1 clinical trial of first-in-class CBA-1205
December 24, 2021
Supplement Documents for Financial Results Q3 FY12/21
November 12, 2021
Non-Consolidated Financial Results (Japanese GAAP) for the Nine Months Ended September 30, 2021
November 12, 2021
Chiome Bioscience : Supplement Documents for Financial Results Q2 FY12/21
August 13, 2021
Chiome Bioscience : Non-Consolidated Financial Results (Japanese GAAP) for the Six Months Ended June 30, 2021
August 13, 2021
Chiome Bioscience : Termination of Collaborative Development License and Exclusive Option Agreement for anti-Semaphorin 3A antibody
May 14, 2021
Chiome Bioscience : Non-Consolidated Financial Results (Japanese GAAP) for the Three Months Ended March 31,2021
May 14, 2021
Chiome Bioscience : Supplement Documents for Financial Results Q1 FY12/21
May 14, 2021
Chiome Bioscience : Collaborative Research Agreement with Mologic Ltd. for antibody discovery and development
May 14, 2021
Chiome Bioscience : Supplement Documents for Financial Results Q2 FY12/20
August 11, 2020
Chiome Bioscience : Non-Consolidated Financial Results (Japanese GAAP) for the Six Months Ended June 30, 2020
August 11, 2020